Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$1.17M$1.17M+53.3% vs Q2 2023 Net Income-$2.19M-$2.19MN/M vs Q2 2023 EPS Diluted-$0.25-$0.25N/M vs Q2 2023 Operating Income-$2,308,065N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-197.4%+344.7 pt vs Q2 2023
Net margin-187.5%
ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end